Literature DB >> 6309889

Thyroid hormone and immunological studies in endemic goiter.

M A Boukis, D A Koutras, A Souvatzoglou, A Evangelopoulou, M Vrontakis, S D Moulopoulos.   

Abstract

Iodized oil (1 ml im) was given to 58 goitrous patients from a mildly iodine-deficient area in Greece. Goiter size, urinary iodine, and serum T4, T3RU, T3, rT3, TSH, thyroxine-binding globulin (TBG), and thyroid autoantibodies were measured before and 1, 3, and 6 months after the injection. Goiter size decreased. Serum T4 remained relatively constant, but TBG decreased and therefore T3RU and FTI increased. Serum T3 and rT3 initially decreased (P less than 0.001) and then increased at the sixth month (P less than 0.001), both showing roughly parallel changes. Serum TSH, initially normal (1.42 +/- 0.11 (SEM) mU/liter), decreased to 0.65 +/- 0.01 and 0.76 +/- 0.05 mU/liter at the third and sixth month (difference from baseline P less than 0.001). Thyroid autoantibodies, both against thyroglobulin and the microsomal antigen, were undetectable before treatment, but became positive in 42.8% of the patients 3 and 6 months later. Three patients developed transient hyperthyroidism. This occurred 3 or 6 months after treatment, and was associated with high titers of thyroid autoantibodies. These results indicate that: 1) transient hyperthyroidism may occur after the administration of iodized oil, possibly because of thyroid tissue necrosis and leakage of hormones, and 2) serum TBG decreases after iodized oil, a finding not previously reported and one whose cause is not known.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6309889     DOI: 10.1210/jcem-57-4-859

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  23 in total

Review 1.  Target organ defects in thyroid autoimmune disease.

Authors:  R S Sundick
Journal:  Immunol Res       Date:  1989       Impact factor: 2.829

Review 2.  Goiter and iodine deficiency in Europe. The European Thyroid Association report as updated in 1988.

Authors:  R Gutekunst; P C Scriba
Journal:  J Endocrinol Invest       Date:  1989-03       Impact factor: 4.256

3.  Reappraisal of the risk of iodine-induced hyperthyroidism: an epidemiological population survey.

Authors:  F Azizi; M Hedayati; M Rahmani; R Sheikholeslam; S Allahverdian; N Salarkia
Journal:  J Endocrinol Invest       Date:  2005-01       Impact factor: 4.256

4.  Uptake and metabolism of iodine is crucial for the development of thyroiditis in obese strain chickens.

Authors:  T R Brown; R S Sundick; A Dhar; D Sheth; N Bagchi
Journal:  J Clin Invest       Date:  1991-07       Impact factor: 14.808

5.  Epitope specificity of spontaneous and induced thyroglobulin autoantibodies in the rat.

Authors:  H J De Assis-Paiva; B Champion; D C Rayner; E Colle; A Bone; I M Roitt; A Cooke
Journal:  Clin Exp Immunol       Date:  1988-10       Impact factor: 4.330

6.  Amiodarone and thyroid immunity.

Authors:  R L Kennedy; T H Jones; H N Shaukat
Journal:  BMJ       Date:  1988-09-03

7.  Iodized oil treatment for endemic goiter does not induce the surge of positive serum concentrations of anti-thyroglobulin or anti-microsomal autoantibodies.

Authors:  M Knobel; G Medeiros-Neto
Journal:  J Endocrinol Invest       Date:  1986-08       Impact factor: 4.256

8.  The effect of iodide depletion and supplementation in the Buffalo strain rat.

Authors:  S B Cohen; A P Weetman
Journal:  J Endocrinol Invest       Date:  1988-09       Impact factor: 4.256

9.  Thyroid cancer and thyroiditis in Salta, Argentina: a 40-yr study in relation to iodine prophylaxis.

Authors:  H Rubén Harach; Dardo A Escalante; Ernesto Saravia Day
Journal:  Endocr Pathol       Date:  2002       Impact factor: 3.943

10.  A high iodine intake in Wistar rats results in the development of a thyroid-associated ectopic thymic tissue and is accompanied by a low thyroid autoimmune reactivity.

Authors:  P Mooij; H J de Wit; H A Drexhage
Journal:  Immunology       Date:  1994-02       Impact factor: 7.397

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.